Olema Pharmaceuticals, Inc.
A clinical-stage biopharmaceutical company based in San Francisco that develops targeted therapies for women's cancers, especially breast cancer. Its lead drug candidate, palazestrant (OP-1250), is an oral pill designed to block the estrogen receptor that fuels many breast tumors, offering patients a daily-at-home option instead of an injection. Founded in 2016, the company went public in 2020 to fund its clinical trials.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| FMR LLC | 13G/APassive | 13.8% | 12.08M | Aug 6, 2026 |
| Abigail P. Johnson | 13G/APassive | 13.8% | 12.08M | Aug 6, 2026 |
| BlackRock, Inc. | 13G/APassive | 7.1% | 6.24M | Jul 29, 2026 |
| JANUS HENDERSON GROUP PLC | 13G/APassive | 8.2% | 7.11M | May 15, 2026 |
| Bain Capital Life Sciences Opportunities IV, L.P. | 13G/APassive | 8.15% | 7.47M | May 15, 2026 |
| Raymond Debbane | 13GPassive | 5.1% | 4.46M | Mar 20, 2026 |
| Invus Public Equities, L.P. | 13GPassive | 4.5% | 3.90M | Mar 20, 2026 |
| Invus Public Equities Advisors, LLC | 13GPassive | 4.5% | 3.90M | Mar 20, 2026 |
| Invus Global Management, LLC | 13GPassive | 4.5% | 3.90M | Mar 20, 2026 |
| Siren, L.L.C. | 13GPassive | 4.5% | 3.90M | Mar 20, 2026 |